Finasteride-d9 – 1 mg

Brand:
Cayman
CAS:
1131342-85-2
Storage:
-20
UN-No:
Non-Hazardous - /

Finasteride-d9 is intended for use as an internal standard for the quantification of finasteride (Item No. 14938) by GC- or LC-MS. Finasteride is a 4-azasteroid competitive inhibitor of 5α-reductase type II (IC50 = 4.2 nM) and a derivative of testosterone.{23862} It is 100-fold selective for 5α-reductase type II over type I. Finasteride (10 µM) does not affect the growth of androgen-refractory PC3 prostate cancer cells but increases the protein levels of Nrf2 and heme oxygenase-1 (HO-1).{23866} It decreases prostatic diameter and volume, as well as dihydrotestosterone, but not testosterone, serum levels in dogs with spontaneous benign prostatic hypertrophy when administered at doses of 0.1 and 0.5 mg/kg.{48477} Finasteride reduces testosterone-induced type I procollagen and TGF-β1 protein levels in cultured human scalp dermal fibroblasts in a model of androgenic alopecia when applied at a concentration of 0.1 μM.{23865} Formulations containing finasteride have been used in the treatment of benign prostatic hyperplasia and androgenic alopecia in men.  

 

Available on backorder

SKU: 28482 - 1 mg Category:

Description

An internal standard for the quantification of finasteride by GC- or LC-MS


Formal name: (4aR,4bS,6aS,7S,9aS,9bS,11aR)-4a,6a-dimethyl-N-(2-(methyl-d3)propan-2-yl-1,1,1,3,3,3-d6)-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxamide

Synonyms: 

Molecular weight: 381.6

CAS: 1131342-85-2

Purity: ≥99% deuterated forms (d1-d9)

Formulation: A solid